LSE · BVXP.L
Bioventix PLC
£20.25-£0.25 (-1.22%)
Bioventix PLC’s quoted price sits in the upper half of its reported 52-week range, 10.2% below the high.
Loading market information…
LSE · SCLP.L · GBp
Stock price, earnings
Quote as of Oct 29, 2026, 04:25 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Scancell Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 69.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Scancell Holdings plc’s next earnings report is currently expected on Feb 4, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Scancell Holdings plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The company's pipeline features several promising candidates, including SCIB1, currently in Phase II clinical trials for metastatic melanoma; SCIB2, aimed at non-small cell lung cancer; and Modi-1, which is undergoing Phase I/II studies for various indications such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is advancing Modi-2, a therapeutic agent specifically designed to target homocitrullinated cancer antigens. Its development efforts also encompass SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine engineered to provide protection against the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:05 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£20.25-£0.25 (-1.22%)
Bioventix PLC’s quoted price sits in the upper half of its reported 52-week range, 10.2% below the high.
£0.24+£0.00 (+1.93%)
EKF Diagnostics Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 18.1% below the high.
£5.30£0.00 (0.0%)
4basebio PLC’s quoted price sits in the lower half of its reported 52-week range, 35.37% below the high.
£0.06+£0.00 (+0.92%)
Shield Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 56.0% below the high.
£0.10+£0.00 (+2.63%)
Ondine Biomedical Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.1% below the high.
£6.80+£0.07 (+1.04%)
Hemogenyx Pharmaceuticals Plc’s quoted price sits in the lower half of its reported 52-week range, 44.26% below the high.
£0.06+£0.00 (+8.11%)
hVIVO plc’s quoted price sits in the lower half of its reported 52-week range, 45.45% below the high.
₪0.46-₪0.01 (-1.72%)
BATM Advanced Communications Ltd.’s quoted price sits in the lower half of its reported 52-week range, 44.27% below the high.
